CTSO earnings: next report 2026-11-03, real EPS beat/miss history, analyst consensus Buy, P/E -2.05. Updated 2026-07-23.
Cytosorbents (CTSO) Research Hub
Cytosorbents (CTSO) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 6.41 USD (+1.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.05, market cap 0.02B. This hub links to the full technical, earnings and options research available for CTSO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.41 USD (+1.26%) |
| 52-week range | 6.11 USD – 10.4 USD |
| Trend regime | Range |
| 14-day RSI | 36.6 (Bearish) |
| Trailing P/E | -2.05 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-11-03 |
Available research for CTSO
Covered Call on CTSO: how it works, illustrative setup around the real 6.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CTSO: how it works, illustrative setup around the real 6.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CTSO: how it works, illustrative setup around the real 6.41 USD price, max profit/loss, breakeven and when to use it. Educational.
CTSO technical analysis: range, last 6.41 USD, RSI 36.6, 52w range 6.11 USD–10.4 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CTSO in?
Cytosorbents (CTSO) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is CTSO in an uptrend or downtrend?
As of 2026-09-11, CTSO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CTSO's trailing P/E ratio?
CTSO's trailing P/E is -2.05, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does CTSO next report earnings?
CTSO is next scheduled to report earnings on 2026-11-03, with a consensus EPS estimate of -0.02547 USD.